Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

148.77
+2.031.38%
Post-market: 149.000.2300+0.15%19:58 EDT
Volume:4.63M
Turnover:685.63M
Market Cap:184.58B
PE:-56.89
High:148.94
Open:146.60
Low:145.58
Close:146.74
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.74
T/O Rate:0.37%
Dividend:3.22
Dividend Rate:2.16%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.60
PE(LYR):21.94

Loading ...

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

TIPRANKS
·
Aug 05

Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained

TIPRANKS
·
Aug 05

Street View: Gilead's HIV Strength Outshines Long-Term Competitive Worries

Reuters
·
Aug 05

U.S. Research Roundup-Ametek, Ball Corp, McDonald's

Reuters
·
Aug 05

Switzerland's Sandoz H1 Net Sales Rise on Biosimilar Growth

Reuters
·
Aug 05

Gilead : Truist Securities Cuts Target Price to $150 from $156

THOMSON REUTERS
·
Aug 05

Gilead Corrects Q2 2026 Europe Odefsey Sales to $58 Million

Reuters
·
Aug 05

Dow Jones Top Company Headlines at 7 PM ET: SpaceX Revenue Could Reach $1 Trillion, Elon Musk Says | Paramount's ...

Dow Jones
·
Aug 05

Gilead Forecasts FY26 Yeztugo Revenue at About $1 Billion

Reuters
·
Aug 05

Gilead CEO Daniel O’Day Sells 15,000 Common Shares Worth $1.96 Million

Reuters
·
Aug 05

Gilead Says Q2 2026 Revenue Growth is Driven by Biktarvy, Descovy and Yeztugo Demand, Pricing Gains

Reuters
·
Aug 05

Gilead Sciences Posts Net Loss as R&D Costs from Acquisitions Weigh on HIV Drug Revenue Growth

Deep News
·
Aug 05

Gilead Sciences, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Gilead Exec Says Saw a Softer Hiv Treatment Market in Q2 as People Fell Out of Insurance Plans Due to Eliminated Aca Tax Subsidies - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Raising Full Year Hiv Growth Expectations to 9%-10% Year-over-Year from Prior Guidance of 8% Growth - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Launch Preparations Fully Underway for Anito-Cel Cell Therapy, with Five Months to Go Until FDA Pdufa Date - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Do not Currently Anticipate Pursuing Additional Sizable M&a Transactions This Year - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 05

Gilead Sciences Inc Q2 Adjusted EPS USD -6.75 Vs. IBES Estimate USD -7.24

Reuters
·
Aug 05

Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story

Dow Jones
·
Aug 05